Last 48 quarters of trend data · Healthcare · Vaccines & Infectious Disease
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.10 | — | 1.62 | — | 0.56 | — | — | — | — | — | — | 43.24 | — | — | 0.30 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.17 | — | 51.20 | — | 0.37 | 28.76 | 6.15 | 45.80 | 11.76 | 27.44 | 32.96 | 13.00 | 4.61 | 15.50 | 0.28 | 31.70 | 8.36 | 18.31 | 15.21 | 47.22 | 70.90 |
| — | — | +731.8% | — | -96.9% | +4.8% | -81.3% | +252.4% | +155.1% | +77.0% | +11666.5% | -59.0% | -44.9% | -15.3% | -98.2% | -32.9% | -88.2% | -74.3% | — | +980.8% | — | |
| P/B Ratio | 0.44 | 0.99 | 0.72 | 1.13 | 0.56 | 1.05 | 0.76 | 0.93 | 0.83 | 1.24 | 1.61 | 0.96 | 1.46 | 1.19 | 1.58 | — | 15.77 | 6.62 | 1.77 | 3.33 | 4.10 |
| — | -6.1% | -4.8% | +21.5% | -33.1% | -14.8% | -53.0% | -3.3% | -43.0% | +4.3% | +1.5% | — | -90.7% | -82.1% | -10.6% | — | +284.3% | +69.4% | -70.7% | -59.0% | +14.9% | |
| P/FCF | — | — | — | — | 0.37 | — | — | — | — | 23.67 | — | — | — | 2.20 | 0.49 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | +977.0% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 1.34 | — | 0.17 | — | — | — | — | — | — | 11.06 | — | — | 0.22 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 1.34 | — | 0.17 | — | — | — | — | — | — | 11.06 | — | — | 0.21 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -153.3% | 78.5% | 99.7% | 87.9% | 87.1% | 87.9% | 89.1% | 85.6% | 72.0% |
| — | — | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | +165.2% | +27.4% | +0.3% | +13.8% | -275.9% | -10.7% | +11.9% | +2.7% | +21.0% | +22.2% | — | -14.4% | — | |
| Operating Margin | -78.0% | — | -3308.5% | — | 56.4% | -2516.5% | -701.0% | -3350.2% | -824.3% | -1563.6% | -1255.0% | -692.5% | -397.9% | -573.4% | 88.6% | -945.3% | -1475.1% | -1400.2% | -1643.1% | -2873.1% | -3734.8% |
| — | — | -372.0% | — | +106.8% | -60.9% | +44.1% | -383.8% | -107.2% | -172.7% | -1516.0% | +26.7% | +73.0% | +59.0% | +105.4% | +67.1% | +60.5% | +62.8% | — | -21619.3% | — | |
| Net Margin | -41.8% | — | 3147.7% | — | 65.7% | -2572.2% | -504.8% | -2097.7% | -453.7% | -425.5% | -1964.4% | 29.9% | -337.9% | -99.8% | 93.0% | -2997.9% | -946.8% | -1900.1% | -1008.7% | -793.4% | -4898.3% |
| — | — | +723.6% | — | +114.5% | -504.6% | +74.3% | -7107.5% | -34.3% | -326.4% | -2212.1% | +101.0% | +64.3% | +94.7% | +109.2% | -277.8% | +80.7% | -1520.6% | — | -1944.7% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.5% | -13.4% | 13.7% | -47.0% | 28.6% | -21.2% | -14.5% | -10.2% | -7.8% | -4.7% | -21.5% | 0.6% | -23.7% | -1.9% | 387.1% | — | -141.2% | -94.4% | -31.6% | -13.6% | -74.2% |
| — | +36.8% | +194.3% | -360.1% | +466.1% | -349.8% | +32.6% | -1926.7% | +67.1% | -148.7% | -105.6% | — | +83.2% | +98.0% | +1324.3% | — | -90.4% | -5355.1% | -655.4% | +29.2% | +71.9% | |
| ROA | -11.5% | -11.8% | 9.7% | -31.2% | 22.3% | -15.4% | -10.7% | -6.8% | -4.7% | -2.7% | -12.8% | 0.3% | -14.1% | -1.2% | 108.6% | -42.9% | -14.4% | -23.9% | -10.8% | -4.7% | -25.5% |
| — | +23.0% | +190.5% | -358.4% | +576.4% | -466.2% | +16.3% | -2140.8% | +67.0% | -134.4% | -111.8% | +100.8% | +1.9% | +95.1% | +1105.8% | -809.6% | +43.4% | -4456.5% | -820.3% | -2.1% | +58.5% | |
| ROIC | -28.2% | -13.2% | -17.9% | -68.7% | 29.2% | -21.1% | -17.5% | -12.7% | -12.0% | -16.2% | -13.4% | -13.3% | -29.7% | -13.6% | 418.1% | — | -1099.9% | — | — | — | — |
| — | +37.6% | -2.3% | -439.2% | +343.8% | -30.6% | -30.7% | +4.0% | +59.8% | -19.4% | -103.2% | — | +97.3% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.03 | 0.03 | 0.05 | 0.04 | 0.06 | 0.05 | 0.05 | 0.30 | 0.27 | 0.26 | 0.21 | 0.21 | 0.16 | 0.16 | — | 15.03 | 2.82 | 1.07 | 1.23 | 1.06 |
| — | -50.8% | -45.9% | +1.4% | -85.1% | -76.9% | -79.1% | -76.1% | +42.9% | +68.8% | +62.9% | — | -98.6% | -94.3% | -85.2% | — | +1321.6% | +148.0% | -21.2% | +105.9% | +21.3% | |
| Debt / EBITDA | — | — | 0.26 | — | 0.18 | — | — | — | — | — | — | 13.28 | — | — | 0.13 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.04 | 7.57 | 9.65 | 3.94 | 7.04 | 5.75 | 5.20 | 5.83 | 3.00 | 3.13 | 3.75 | 3.72 | 6.26 | 7.66 | 9.01 | 1.31 | 4.49 | 7.26 | 7.85 | 7.87 | 8.03 |
| — | +31.7% | +85.6% | -32.4% | +135.1% | +83.8% | +38.8% | +56.8% | -52.2% | -59.2% | -58.4% | +183.9% | +39.6% | +5.5% | +14.8% | -83.4% | -44.1% | -7.6% | +34.9% | +105.8% | +115.9% | |
| Quick Ratio | 7.04 | 7.57 | 9.65 | 3.94 | 7.04 | 5.75 | 5.20 | 5.83 | 3.00 | 3.13 | 3.75 | 3.72 | 6.26 | 6.88 | 8.37 | 1.29 | 4.44 | 7.21 | 7.81 | 7.78 | 8.00 |
| — | +31.7% | +85.6% | -32.4% | +135.1% | +83.8% | +38.8% | +56.8% | -52.2% | -54.5% | -55.2% | +189.3% | +41.2% | -4.5% | +7.2% | -83.5% | -44.5% | -7.8% | +34.4% | +103.5% | +115.0% | |
| Interest Coverage | -48.76 | — | — | — | — | — | — | -30.16 | -6.22 | -4.57 | -23.08 | 1.89 | -31.41 | -2.07 | 38.65 | -22.41 | -6.70 | -15.89 | -7.08 | -6.27 | -20.97 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SCYX stock.
SCYNEXIS, Inc.'s current P/E is -4.1x. The average P/E over the last 2 quarters is 1.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
SCYNEXIS, Inc.'s current operating margin is -78.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking SCYNEXIS, Inc.'s business trajectory between earnings reports.